



## Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences

May 12, 2021

*2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021 at 3:05 pm ET*

*Oppenheimer Rare & Orphan Disease Summit on Friday May 21, 2021 at 4:35 pm ET*

DALLAS--(BUSINESS WIRE)--May 12, 2021-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference and a virtual presentation at the Oppenheimer Rare & Orphan Disease Summit.

### Conference Details:

Event: 2021 RBC Capital Markets Global Healthcare Conference

Date: Wednesday, May 19, 2021

Time: 3:05 pm ET

Format: Fireside chat

Participants: RA Session II, President, Founder and CEO

Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development

Kamran Alam, Chief Financial Officer

Event: Oppenheimer Rare & Orphan Disease Summit

Date: Friday, May 21, 2021

Time: 4:35 pm ET

Format: Presentation

Participants: RA Session II, President, Founder and CEO

Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development

Kamran Alam, Chief Financial Officer

Webcasts for these conferences will be available in the "Events & Media" section of the Taysha corporate website at <https://ir.tayshagtx.com/news-events/events-presentations>. Archived versions of the webcasts will be available on the website for 60 days.

### About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients' lives. More information is available at [www.tayshagtx.com](http://www.tayshagtx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210512006057/en/): <https://www.businesswire.com/news/home/20210512006057/en/>

### Company Contact:

Kimberly Lee, D.O.

SVP, Corporate Communications and Investor Relations

Taysha Gene Therapies

[klee@tayshagtx.com](mailto:klee@tayshagtx.com)

### Media Contact:

Carolyn Hawley

Canale Communications

[carolyn.hawley@canalecomm.com](mailto:carolyn.hawley@canalecomm.com)

Source: Taysha Gene Therapies, Inc.